Premium Nahrungsergänzungsmittel | artgerecht

AOD-9604: Peptide for Fat Burning

AOD-9604 is a synthetic peptide derived from human growth hormone, studied for its fat-burning and weight management properties.

Regular tips about health Regular tips about health

Things worth knowing about "AOD-9604"

AOD-9604 is a synthetic peptide derived from human growth hormone, studied for its fat-burning and weight management properties.

What is AOD-9604?

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide derived from the C-terminal fragment of human growth hormone (hGH), specifically encompassing amino acids 177 to 191. It was originally developed as a potential treatment for obesity. Unlike the full-length growth hormone, AOD-9604 does not affect insulin levels or stimulate cell growth; instead, it specifically targets fat metabolism.

Mechanism of Action

AOD-9604 mimics the lipolytic (fat-breaking) properties of natural growth hormone without triggering its anabolic (tissue-building) effects. The key mechanisms include:

Lipolysis: AOD-9604 stimulates the breakdown of stored fat cells (triglycerides) into free fatty acids, which are then used as an energy source.
Inhibition of Lipogenesis: The peptide inhibits the formation of new fat tissue from carbohydrates and other nutrients.
Beta-3 Adrenergic Receptors: AOD-9604 interacts with beta-3 adrenergic receptors in adipose tissue, further promoting fat breakdown.
No IGF-1 Stimulation: Unlike full-length growth hormone, AOD-9604 does not stimulate the production of Insulin-like Growth Factor 1 (IGF-1), thereby avoiding unwanted growth-related side effects.

Medical Research and Applications

AOD-9604 was originally developed by the Australian pharmaceutical company Metabolic Pharmaceuticals and investigated in clinical trials for its potential to treat obesity. Preclinical studies demonstrated promising results in reducing body fat. However, Phase II and Phase III clinical trials in humans did not provide sufficient evidence of significant weight reduction, and the peptide has not received regulatory approval as an anti-obesity drug to date.

Beyond weight management, AOD-9604 is being explored for additional potential therapeutic applications, including:

Cartilage Regeneration: Some preclinical studies suggest a possible role in repairing cartilage tissue, making it of interest for osteoarthritis treatment.
Bone Health: There is preliminary evidence suggesting a potential positive effect on bone density.
Anti-inflammatory Properties: Early research indicates possible anti-inflammatory effects.

Usage and Dosage

AOD-9604 is not available as an approved pharmaceutical drug and is therefore not officially recommended for medical treatment. It is, however, commonly used in research settings and within the field of so-called peptide therapy. Typical dosages used in studies were 1 mg per day, administered as a subcutaneous injection. Oral formulations have also been investigated, though bioavailability is considerably lower compared to injection.

Since AOD-9604 is not a licensed medication, dosages used in practice vary widely and are not standardized by clinical guidelines. Use should only occur under medical supervision.

Side Effects and Safety

In clinical studies, AOD-9604 demonstrated a favorable safety profile. Because the peptide does not affect IGF-1 or insulin levels, typical side effects associated with growth hormone therapy -- such as insulin resistance or abnormal organ growth -- are not observed. Reported side effects include:

Local reactions at the injection site (redness, swelling)
Headache
Nausea (in rare cases)
Dizziness

As long-term human data remain limited, caution is advised. Use without medical supervision is not recommended.

Regulatory Status

AOD-9604 is not registered as an approved pharmaceutical in most countries, including Germany, the European Union, and the United States. It is listed by the World Anti-Doping Agency (WADA) on its Prohibited List for sport. Possession and use may therefore be subject to legal restrictions depending on the country.

References

Ng FM et al. - Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Clinical and Experimental Pharmacology and Physiology, 2000.
World Anti-Doping Agency (WADA) - Prohibited List 2024. wada-ama.org
Heffernan M et al. - The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology, 2001.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.